URGN - UroGen: Q3 NDA Opens Hefty Revenue Opportunity

2024-06-17 09:00:00 ET

Summary

• ENVISION DOR data released in Q2, 2024 showed an unprecedented 82.3% Duration of Response for UGN-102.
• Following such positive data, it expects to make an FDA submission late in Q3, 2024, with potential for priority review.
• UroGen Pharma's blockbuster drug potential, liquidity, and modest market cap make it a strong buy.

1. This is my third UroGen Pharma Therapeutics ( URGN ) article after 03/2023's "UroGen: All Eyes On UGN-102 (" Eyes "). I concluded the article, noting that:

Those interested in this name will be attuned to its ENVISION DOR data expected for release in Q2, 2024. Assuming positive data the next point to watch for will be an FDA submission late in Q3, 2024. Next will be the FDA's response to UroGen's NDA; did it accept the filing and grant priority review?

For further details see: